Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
CTMX
#2625
CytomX Therapeutics, Inc.
4.5
4
USD
+3.42%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+3.42%
Changement Mensuel
-34.30%
Evolution sur 6 mois
+31.21%
Changement Annuel
+632.26%
Clôture Précédente
4.3
9
Open
4.5
4
Bid
Ask
Low
4.5
4
High
4.5
4
Volume
177
Marchés
Actions des Marchés US
Soins de Santé
CTMX
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
64.78 M
65.39 M
66.23 M
67.72 M
80.1 M
170.19 M
—
Valuation ratios
Enterprise value
232.48 M
77.62 M
-87.02 M
97.28 M
44.45 M
712.33 M
1.55 B
Price to earnings ratio
—
—
-1.07
-169
2.71
-28.4
-15.05
Price to sales ratio
—
—
1.99
1.23
0.63
7.71
12.15
Price to cash flow ratio
—
—
-0.96
-2.23
-1.01
-7.77
-15.75
Price to book ratio
—
—
-1.23
-2.63
-191.42
5.93
8.31
Enterprise value to EBITDA ratio
-5.02
-0.96
0.88
-8.27
2.07
-30.67
1.18
Profitability ratios
Return on assets %
-0.09
-0.25
-0.38
-0
0.26
-0.11
-0.03
Return on equity %
-0.66
-0.94
1.16
0.01
-69.89
-0.18
0.54
Return on invested capital %
-137.42
-322.4
-333.03
2.95
82.29
-145.89
-351.48
Gross margin %
100
100
100
100
100
100
400
Operating margin %
-48.43
-120.42
-190.61
-6.41
18.1
-29.35
-4 439.72
EBITDA margin %
-46.13
-116.08
-186.11
-11.62
15.52
-30.48
-4 537.54
Net margin %
-32.77
-120.17
-186.82
-0.56
23.08
-22.79
-4 191.74
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
3.21
2.92
1.55
1.17
1.25
3.09
12.65
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.29
0.2
0.18
0.44
0.86
0.56
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-1.69
-0.76
-1.02
-0.55
-0.63
EBIT per share
—
—
-1.54
-0.09
0.29
-0.16
-0.05
EBITDA per share
—
—
-1.51
-0.16
0.25
-0.17
-0.06
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
1.45
2.38
1.2
0.99
4.01
Net current asset value per share
—
—
3.61
2.48
1.27
1.04
4.22
Tangible book value per share
—
—
-1.33
-0.67
-0.02
0.71
2.54
Working capital per share
—
—
1.29
0.37
0.25
0.71
2.75
Book value per share
—
—
-1.3
-0.64
-0.01
0.72
2.59
Nouvelles
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Jefferies réitère sa recommandation d’achat sur CytomX après les données de phase 1
3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts - TipRanks.com
Piper Sandler relève l’objectif de cours de CytomX sur la base de données d’essais cliniques
Pourquoi l'action de CytomX Therapeutics baisse-t-elle le mercredi ? | Benzinga France
Jefferies relève l’objectif de cours de CytomX sur fond de données ADC
CytomX fixe le prix d’une offre d’actions de 250 millions $ à 5,30 $ par action
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTMX) 2026-03-17
CytomX launches $250M public offering to fund drug development
Micron and Intel among market cap stock movers on Monday
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) (CTMX)